In Brief
While anti-cytokine therapies show promising results in autoimmune diseases, its effects on cardiovascular disease development are not well understood. Fatkhullina and colleagues show that inactivation of IL-23-IL-22 signaling leads to deterioration of the intestinal barrier, expansion of proatherogenic bacteria, and production of metabolites promoting macrophage activation and atherosclerosis.
INTRODUCTION
Atherosclerosis is a lipid-driven, chronic inflammatory disease mediated by activated immune cells in the arterial wall (Galkina and Ley, 2009) . A cross talk between the innate and adaptive immune cells, and non-hematopoietic cells in the aortic wall, is mediated by a number of cytokines, which regulate atherogenesis (Ait-Oufella et al., 2011; Hansson and Hermansson, 2011) . Elevated concentration of specific cytokines in human and rodent plasma and aortic tissue are linked to atherosclerosis progression (Caligiuri et al., 2003; Han et al., 2010) . Anti-cytokine therapies show promising results in many autoimmune diseases, including inflammatory bowel disease (IBD), psoriasis and arthritis (Gaffen et al., 2014) and, recently, atherosclerosis (Ridker et al., 2017) .
Interleukin (IL)-23 is a member of the IL-6-IL-12 family of cytokines and a heterodimer of p19 (unique) and p40 (shared with IL-12) subunits. The IL-23 cytokine axis drives several chronic inflammatory diseases, including arthritis, psoriasis, IBD, and cancer; and genetic inactivation or pharmacological blockade of IL-23 generally suppresses disease development (Cua et al., 2003; Hue et al., 2006) . IL-23 is a known regulator of IL-17A and IL-22 cytokine production (Gaffen et al., 2014) . The role of IL-17A in atherosclerosis has been extensively investigated (Taleb et al., 2010) . The mechanisms of IL-22 action in atherosclerosis remain largely unknown, although it has been reported that IL-22 suppresses metabolic disorders and regulates lipid metabolism in the liver and adipose tissue (Behnsen et al., 2014; Wang et al., 2014a ). An elevated IL-23 has been reported in aortic tissue of mice and humans with cardiovascular diseases (CVD) (Abbas et al., 2015) , while it is reduced in PBMCs of patients with CVD (KhojastehFard et al., 2012) . IL-23 has also been implicated in the regulation of cardiac inflammation, as Il23 -/-mice display increased injury and adverse remodeling after myocardial infarction (Savvatis et al., 2014) . Although data in other inflammatory models suggest that IL-23 might potentially function to promote atherosclerosis, the exact role of this cytokine remains unknown.
Microbial and viral components of commensal and pathogenic flora (collectively ''microbiome'') are key emerging factors that regulate cytokine production and differentiation of cytokine-producing cells (Ivanov et al., 2009; Khosravi and Mazmanian, 2013) . Emerging evidence demonstrates that commensal microbiota have direct effects on immune system activation and inflammatory responses, playing a key role in regulating chronic inflammatory diseases, including rheumatoid arthritis, IBD and, recently, atherosclerosis (Jonsson and B€ ackhed, 2017) . Microbiome alterations might systemically impact the progression of distant disease via produced metabolites that increase cardiovascular risk (Jonsson and B€ ackhed, 2017) . Therefore, changes in gut microbiota caused by dietary factors, stress, or use of antibiotics, may profoundly impact the development of chronic inflammatory diseases, potentially including atherosclerosis. To date, the mechanisms controlling the interplay between diet, cytokine and immune signaling, and microbiota in atherosclerosis are largely unknown.
Here, we uncovered an atheroprotective role of IL-23-IL-22 signaling. We found that IL-23 and IL-22 shape gut microbiota by regulating the production of antimicrobial peptides and restraining the expansion of the semi-invasive bacterial species with pro-atherogenic properties. Metagenomic sequencing and metabolomics along with functional experiments demonstrated that these bacteria promoted atherosclerosis progression particularly by producing lipopolysaccharide (LPS) and components of the trimethylamine N-oxide (TMAO) biosynthesis pathway, upregulating the expression of pro-atherogenic osteopontin (OPN) and facilitating the activation of Ly6C hi monocytes and aortic macrophages. Using genetic, pharmacological, and other approaches, we delineated the mechanisms of cytokinemicrobiota-mediated pathway that distantly controls atherosclerosis progression. Our data argues for informed application and further clinical studies of IL-23 and especially IL-22 blockers in individuals with sub-optimal dietary habits and those predisposed to atherosclerosis.
RESULTS

IL-23 Deficiency Aggravates Atherosclerosis
IL-23 cytokine and its downstream target IL-17A have been implicated in the pathogenesis of several autoimmune diseases (Gaffen et al., 2014) and cancer (Grivennikov et al., 2012) . The fact that IL-23 regulates pro-atherogenic IL-17A led us to hypothesize that IL-23 might be pathogenic in atherosclerosis. Because both IL-23 and its cognate receptor IL-23R are primarily expressed within the hematopoietic compartment, we used a bone marrow (BM) chimera approach to ablate IL-23 signaling in hematopoietic cells in an atherosclerosis-prone mouse model. Figure 1E ). Since IL-23 is known to regulate the production of IL-17A by T helper and ILC3 cells, we assayed IL-17A by Q-RT-PCR and intracellular cytokine staining. We did not find any differences in IL-17A between Il23 -/-/Ldlr -/-and WT/Ldlr -/-mice ( Figure 1E and Figure S2C ) suggesting that IL-23 may be dispensable for its expression in the atherosclerotic aorta. As previous studies have demonstrated that IL-23 is required for regulating intestinal inflammation (Ahern et al., 2010) , we examined inflammatory gene expression in the intestine of mice with atherosclerosis. Consistently, we found a reduction of Il1b, Tnf, Ccl2, Ccl5, Cxcl1 , and Il22 gene expression in the intestines of Il23 -/-/Ldlr -/-mice compared to WT/ Ldlr -/-controls ( Figure 1F and Figure S2D ). Overall, these findings suggest that IL-23 signaling suppresses atherosclerosis.
Inactivation of IL-22 Exacerbates Atherosclerosis
Because IL-23 is also known to regulate IL-22 expression (Zheng et al., 2008) (Figures 2A-2C ). Il22 -/-/Ldlr -/-mice were characterized by an increased accumulation of T cells and myeloid cells (Figures 2D and S2E and S2F) in the aortas, and by an upregulation of inflammatory gene expression in aortas and intestines ( Figures 2E and 2F ). Transfer of IL-22 deficient BM resulted in strong downregulation of intestinal IL-22 ( Figure S2G ). We also observed that IL-22-producing CD90.2 + ILC3 and T cells were almost exclusively donor-derived ( Figure S2H ), thereby excluding incomplete BM repopulation or IL-22 production by residual radio-resistant cells. In agreement with our observation of enhanced atherosclerosis in Il23 -/-/Ldlr -/-and Il22 -/-/Ldlr -/-mice, we found an increased number of apoptotic cells (Figure S3A) and smooth muscle cells ( Figure S3B ) in the aortas.
No difference was detected in tissue repair macrophage genes, IL-12 or lipid transporters expression ( Figures S3C-S3E ).
To examine whether IL-23 may restrain atherosclerosis via direct induction of IL-22, we performed a ''gain-of-function'' experiment, testing whether in vivo supplementation of IL-22 would rectify the pro-atherogenic effects of IL-23 deficiency.
We administered (Zheng et al., 2008 ). Therefore, we tested whether IL-23 or IL-22 deficiency altered the microbiome and epithelial homeostasis in WD-fed, atherosclerosis-prone mice. We found that intestines of WD-fed Il23 -/-/Ldlr -/-and Il22 -/-/Ldlr -/-mice displayed a significant reduction of the anti-microbial peptides Reg3b and Reg3g expression compared to WT/Ldlr -/-controls ( Figure 3A ). Immunostaining revealed RegIIIg downregulation, as well as a strong reduction in Mucin2, a key component of mucus ( Figure 3B ). mice. These bacterial families have been suggested to be pro-inflammatory or pro-atherogenic (Elinav et al., 2011; Fu et al., 2015; Gregory et al., 2015; Kelly et al., 2016 Figure S4E ) similarly to found in BM transplanted mice ( Figure 1F Figure S5A -S5C) and reduced anti-microbial peptides expression ( Figure S4E ), similarly to Figure S4F ).
Therefore, IL-23 and IL-22 are required to regulate intestinal homeostasis to prevent outgrowth of pathogenic bacteria and excessive accumulation of bacteria in a close proximity to the epithelium. The exacerbated atherosclerosis observed in the absence of IL-23 or IL-22 is driven directly by microbes, as the atherosclerotic phenotype is accompanied by changes in luminal and mucosa-associated microbes is ''transferrable'' to WT recipient by microbiota from IL-23-deficient donor and can be reversed by microbiota ablation. These bacterial pathways, including LPS biosynthesis, N-glycosylation, and specific lipid biosynthesis, have been suggested to be pro-inflammatory (Hornemann and Worgall, 2013) . A protein domains structure prediction, performed on metagenomic sequencing data, demonstrated the upregulation of the LPS biosynthesis as the most significantly changed pathway (Figures 5A-5C), therefore, suggesting that the disruption of IL-23-IL-22 signaling leads to the enrichment of bacterial species capable of producing pro-inflammatory metabolites. This enrichment in bacteria and their closer adherence to the epithelium may allow release of the bacterial metabolites into the systemic circulation, thereby promoting atherosclerosis. In agreement with this idea, we found elevated LPS in sera of both IL-23-and IL-22-deficient Ldlr -/-mice ( Figure 5D ), implying that the expansion of pathogenic flora may contribute to low-grade systemic inflammation. Importantly, administration of mIL-22-Ig, which ''rescues'' the IL-23-deficient phenotype ( Figure 2H ), also reduced serum LPS ( Figure 5E ) along with ''normalizing'' microbiota (Figure S5D) . Consistently, microbiota depletion by antibiotics reduced serum LPS concentration ( Figure 5F ), while fecal transplant from IL-23-deficient atherosclerotic donors increased it in WT/Ldlr -/-mice ( Figure 5G ).
Next, to characterize additional mechanistic cues originating from the microbiota and promoting atherosclerosis, we performed discovery metabolomics on serum samples from Il23
, and WT/Ldlr -/-mice fed with WD for 16 weeks. We detected an increased presence of metabolites related to trimethylamine N-oxide (TMAO) production, including phosphatidylcholine, choline, betaine, and trimethylamine (TMA) ( Figure 5I ), as well as others ( Figure S6 ). These results were in line with an increased presence of bacterial genes encoding for choline-trimethylamine lyase (a TMA biosynthesis Figure 5H ). A similar upregulation of TMAO pathway metabolites was detected in WT/Ldlr -/-recipients of fecal microbiota from IL-23-deficient donors ( Figure 5I and S6D). The chemical detection of these metabolites was consistent with metagenome shotgun analysis and 16S rRNA sequencing of luminal and adhesive bacteria, which revealed overrepresentation of bacteria associated with TMAO pathway metabolism and increased presence of choline trimethylamine lyase bacterial gene ( Figure 3D , 3H, 5H). Importantly, TMAO serum concentrations were further elevated in Ldlr -/-x Il23 -/-mice fed with WD diet containing 1% choline, a direct metabolic precursor, which is converted into TMAO by bacteria dependent mechanisms ( Figure 5J ).
Overall, these data suggest a mechanistic connection between disrupted IL-23-IL-22 cytokine signaling, a reduction in colonic epithelial barrier function, expansion of pathogenic microbiota, elevated bacteria-derived metabolites in the serum, and atherosclerosis progression, perhaps via induction of lowgrade inflammation.
Osteopontin Upregulation Links Microbial Changes to Progression of Atherosclerosis
To further determine how the cytokine ablation and dysbiosis affect inflammatory responses in the aortas, we analyzed inflammatory gene expression and found osteopontin (OPN, Spp1) as highly upregulated gene in aortas of Figure 6A ). OPN, a secreted inflammatory protein, has been implicated in various inflammatory conditions and suggested to play a role in atherosclerosis (Isoda et al., 2003; Kahles et al., 2014; Matsui et al., 2003) . We found that OPN protein was highly expressed in CD11b + CD11c -macrophages in the aortas ( Figure 6B ), while its expression was modest in macrophages Figure S4 . Figure 6I ). Finally, we tested whether metabolites elevated in IL-23-and IL-22-deficient mice could directly promote OPN expression and atherosclerosis progression. We treated mice for 3 weeks with LPS and TMAO and found that combined administration of these metabolites accelerated atherosclerosis development in WD-fed Ldlr -/-mice (Figures 7A and 7B) along with upregulation of Spp1, Cd36, and Il1b gene expression in aortas ( Figure 7C ). Similar results were obtained when explanted aortas were stimulated with LPS and TMAO ex vivo ( Figure S7D ). We further found that acute in vivo administration of LPS and TMAO enhances Spp1 expression in circulating Ly6C hi monocytes ( Figure 7D ), suggesting that OPN may become upregulated in circulating cells. It is conceivable that these pre-activated monocytes are then recruited to atherosclerotic plaques, where they differentiate into macrophages and produce more OPN in an environment rich in OPN-inducing stimuli.
Together, these data suggest that OPN is an important driver of atherosclerosis and its expression is regulated by pathogenic microbiota and metabolites, which are kept at bay by a functional IL-23-IL-22 pathway. Altogether, a functional atheroprotective IL-23-IL-22 axis maintains intestinal homeostasis and normal host-microbe interactions, and prevents outgrowth of epitheliaassociated, pro-atherogenic bacteria. These bacteria deliver pro-atherogenic metabolites, such as LPS and TMAO systemically due to the defective intestinal barrier. These metabolites conspire with additional pro-atherogenic factors to enhance the activation of circulating monocytes and pathogenic inflammatory macrophages promoting atherosclerosis, particularly in OPNdependent manner.
DISCUSSION
A field connecting the diet-modulated microbiome and metabolic diseases has recently emerged. Microbial alterations have been shown to regulate cytokine production, which is required for host defense against intestinal infections (Belkaid and Hand, 2014) . Conversely, cytokine signaling has been also implicated in the regulation of host-microbiome interactions during infections (Kamada et al., 2013) . Because atherosclerosis is an inflammatory disease, it could be expected that cytokine blockade, which has been effective in multiple forms of autoimmunity, might be beneficial against this chronic CVD condition as exemplified by the recently completed CANTOS trial (Ridker et al., 2017) . However, the fact that cytokines are important regulators of host-microbial interactions provides an alternative possibility, namely that cytokine blockade will alter distinct qualitative and quantitative characteristic of the microbiota, further affecting metabolic parameters. Both of these possibilities were largely unexplored, especially for a cytokine like IL-23, whose role in atherosclerosis remains elusive.
Our work reveals that cytokine signaling, which plays a key role in driving systemic inflammation, is also involved in homeostatic regulation of intestinal epithelial cells, controlling expansion of atherogenic microbiota. We have shown that genetic inactivation of either IL-23 or its receptor, IL-23R, aggravated atherosclerosis progression in a long-term model, which allows microbiota alterations to develop and microbiota-driven changes to manifest. In previous studies, systemic expression of IL-23 in a transgenic model induced an inflammatory phenotype and promoted various inflammatory diseases, predisposing to atherosclerosis (Wiekowski et al., 2001 ). Short-term IL-23 injections have been shown to increase apoptosis in plaques, likely acting in a GM-CSF-dependent manner, and it was shown that early lesions could develop unperturbed in the absence of IL-23R (Engelbertsen et al., 2018; Subramanian et al., 2015) . In our model, genetic inactivation of IL-23 resulted in an increased number of apoptotic cells in atherosclerotic plaques, confirming that apoptosis in the plaque is tightly linked to atherosclerosis progression.
While we originally hypothesized that IL-23 would regulate IL-17A expression in the aorta and thereby would promote atherosclerosis in IL-17A-dependent manner, we did not find any differences in IL-17A expression in the aortas of IL-23-or was also previously suggested (Rattik et al., 2015) . Administration of IL-22 suppressed the disease in IL-23-deficient mice, implying IL-22 as a critical mediator downstream of IL-23. The observed differences in phenotypes may be attributed to several factors, including possible genetic variations between the mice used or differences in the microbiome of non-cohoused and non-littermate animals, supporting the hypothesis that IL-22 has an important microbiome-regulatory role in atherosclerosis. Cytokine signaling in intestinal epithelial cells has been suggested to modulate microbiota composition (Belkaid and Hand, 2014; Kamada et al., 2013) . IL-22 has been found to control epithelial cell proliferation and antimicrobial peptide production, limiting the ability of commensal bacteria to cause inflammation (Behnsen et al., 2014; Sugimoto et al., 2008) . Changes in the production of anti-microbial peptides therefore can result in the expansion of bacterial species with potentially pathogenic properties and their localization in direct proximity to intestinal epithelium. In agreement, we found a significant reduction of RegIIIg and Mucin 2 in Il22 -/-/Ldlr -/-and Il23 -/-/ Ldlr -/-atherosclerotic mice, which correlated with a high amount of tightly adhesive bacteria including Clostridiaceae and Ruminococcaceae known to contribute to mucus layer degradation (Desai et al., 2016; Tailford et al., 2015) . Quantitative alterations of the microbiome have been associated with diseases, including IBD, metabolic disorders, cancer, and atherosclerosis (Elinav et al., 2011; Goodman and Gordon, 2010; Wang et al., 2011) . We found that the augmented atherosclerosis progression in WD-fed Il23 -/-
/Ldlr
-/-and Il22 -/-/ Ldlr -/-mice was associated with the enrichment in bacteria with previously suggested pro-inflammatory and pro-atherogenic roles (Kelly et al., 2016; Wang et al., 2015) . Conversely, potentially protective Odoribacteriaceae were detected in WT/Ldlr -/-, but not Il23
/Ldlr -/-mice. As microbiome alterations could systemically impact distant disease progression via release of metabolites (Postler and Ghosh, 2017; Schroeder and B€ ackhed, 2016) , we found that the IL-23-IL-22-microbiota axis was essential for regulating several relevant bacterial functional and metabolic pathways, and thus, atherosclerosis. One large group of these pathways increased the adhesiveness of bacteria, the synthesis of toxic bacterial products such as N-glycans, and the sphingolipid biosynthesis pathway. LPS biosynthesis, however, was the highest among the upregulated pathways. Deterioration of epithelial barrier function and adhesiveness of bacteria to the epithelium, combined with elevated biosynthesis of these metabolites, is likely to functionally contribute to the increased systemic concentration of LPS detected in atherosclerotic mice with IL-23 or IL-22 ablation. Alterations of other pathways, found by metagenomics shotgun sequencing were also confirmed by discovery metabolomics detecting elevated presence of phosphatidylcholine, choline, TMA and trimethylamine-N-oxide (TMAO) in serum of Il23 -/-/Ldlr -/-mice. Among them, TMAO has been implicated in the pathogenesis of atherosclerosis in humans and mice consuming a choline-rich diet (Wang et al., 2011) . Increased TMAO production in the absence of IL-23 pathway was further elevated by feeding with choline rich WD, implying that IL-23-IL-22-microbiota-TMAO pathway may be especially important in individuals with different sub-optimal dietary habits. Serum TMAO positively correlated with enrichment for certain bacteria, including the Prevotellaceae, Enterobacteriaceae, Ruminococcaceae, and Clostridiaceae, linked to TMAO production and atherosclerosis progression in correlation studies in humans (Brusca et al., 2014; Fu et al., 2015; Gregory et al., 2015; Kelly et al., 2016; Yan et al., 2017) . Moreover, metagenomics data revealed increased presence of the bacterial gene encoding for choline-trimethylamine lyase in IL-23 and IL-22 deficient mice, providing linear connection between dysbiosis, pathogenic metabolites, and atherosclerosis. The data obtained from the bacterial pathways analysis might be highly relevant to humans, who are much more diverse in microbes and might harbor pathogenic and protective microbes of different species, but with similar metabolic and biosynthetic profiles. While metabolites like TMAO and LPS can potentially drive atherosclerosis directly, they can also regulate inflammatory intermediates essential for disease pathogenesis. Indeed, enhanced atherosclerosis in the absence of IL-23-IL-22 pathway was accompanied by increased systemic inflammation. We found strong upregulation of osteopontin (Spp1) Figure S6 . (legend continued on next page) activation of both adaptive and innate immune cells in inflammatory diseases and cancer (Isoda et al., 2003; Kahles et al., 2014; Matsui et al., 2003) and particularly could act also on circulating monocytes in an autocrine manner in atherosclerosis. Importance of OPN in control of excessive inflammation and atherosclerosis downstream of microbial alterations was illuminated by reduction in OPN after antibiotic treatment, increase in OPN after microbial transfer from Il23 -/-/Ldlr -/-donors and reduction in atherosclerosis after OPN neutralization.
Our data, therefore, suggests a model in which inhibition of IL-23 or IL-22 pathways results in alterations in the microbiome, which, coupled with a reduced anti-microbial, protective epithelial layer, leads to elevated serum concentration of metabolites and bacterial products, such as LPS and TMAO, promoting activation of monocytes and aortic macrophages and further progression of atherosclerosis, particularly in OPN-dependent manner. IL-23-IL-22 cytokine signaling therefore controls qualitative and quantitative characteristics of the microbiota and its pro-atherogenic metabolites and distantly suppresses atherosclerosis via regulation of intestinal homeostasis and inflammation, although we do not exclude an aorta-specific role of these cytokines. Diet and cytokine signaling-induced changes in proatherogenic metabolites regulate OPN expression, inflammation, and atherosclerosis progression. Our findings will be informative about mechanisms underlying cardiovascular adverse effects, which could be observed upon IL-23 and IL-22 cytokine blockade, especially in subjects with elevated cardiovascular risk factors and/or suboptimal dietary habits (e.g., high carbohydrates, fat, or choline containing food). In the long run, inactivation of IL-23-IL-22 axis might exacerbate dormant CVD. As IL-22 is a key cytokine preventing atherosclerosis downstream of IL-23, strategies, which spare IL-22 pathway during cytokine blockade, might be justified. Most importantly, our work demonstrates mechanistic connection between cytokine signaling and host-microbiota interaction in distant regulation of prevalent, diet-driven cardiovascular disease.
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EXPERIMENTAL MODELS AND SUBJECT DETAILS Animals
All animal experiments were approved by the Animal Care Committee at FCCC. Ldlr -/-and Apoe -/-were purchased from Jackson labs. IL-23-, IL-22-deficient mice (Il23p19 -/-referred in the text as Il23 -/-, Il22 -/-) were provided by Genentech Inc. IL-23R deficient mice were initially generated by G. Trinchieri (NCI/NIH) and described (Grivennikov et al., 2012 
IL-22 supplementation experiments
Bone marrow transplanted Il23 -/-/Ldlr -/-and WT/Ldlr -/-mice fed with WD for 8 weeks were injected intraperitoneally (i.p.) every 3 days for 4 weeks with recombinant mouse IL-22 cytokine, kindly provided by Genentech Inc, (50mg per injection) or PBS. Antibiotic treatment experiments At 12 weeks of WD feeding WT/Ldlr -/-, Il23 -/-/Ldlr -/-and Il22 -/-/Ldlr -/-mice were treated with water containing a mix of broadspectrum antibiotics: ciprofloxacin 0.2g/L, neomycin 1g/L, vancomycin 0.5g/L, ampicillin 1g/L, metronidazole 0.5g/L, primaxin 0.5g/L. OPN neutralization experiments 13.5 weeks WD fed WT/Ldlr -/-, Il23
-/-/Ldlr -/-and Il22 -/-/Ldlr -/-mice were injected intraperitoneally (i.p.) every 3 days for 2.5 weeks with mouse OPN-antibody (purified from hybridoma, clone MPIIIB10, DSHB, University of Iowa) (100mg/mouse per injection) or control represented by either PBS or mouse IgG1k isotype control (clone MOPC-21) in 3 independent experiments.
Microbiota transfer experiments Microbiota recipients WT/Ldlr
-/-or Il23 -/-/Ldlr -/-mice were maintained for 8 days with a mix of broad-spectrum antibiotics in drinking water (ciprofloxacin 0.2g/L, neomycin 1g/L, vancomycin 0.5g/L, ampicillin 1g/L, metronidazole 0.5g/L and primaxin 0.5g/L). 24 hours before microbiota transfer, recipient mice were placed on regular water. Microbiota from cecum of WT/Ldlr -/-or Il23 -/-/Ldlr -/-mice fed with WD for 16 weeks was collected, weighted, resuspended at concentration 1g of feces/50ml of PBS and gavaged in PBS in 3 consecutive days after which mice were fed with WD and housed separately for 16 weeks for atherosclerosis studies.
METHODS DETAILS
Bone marrow transplantation Recipient Ldlr -/-mice (6-8 weeks old) were irradiated in 2 equal doses of 600 rads 3-4 hours apart. Femurs and tibias of donor mice
were collected and bone marrow were isolated and resuspended in PBS under sterile conditions. After the second irradiation recipient mice were injected intravenously (i.v.) with 5*10 6 bone marrow cell suspensions and maintained on water, containing antibiotics (neomycin and polymixin B) during first 2 weeks post-transplant. Starting 4 weeks after BMT mice were fed with WD for 16 weeks to promote the atherosclerosis development. Shimadzu Nexera UHPLC system Shimadzu https://www.ssi.shimadzu.com/products/ liquid-chromatography/nexera-x2/nexerauhplc-hplc.html
Quantification of aortic atherosclerotic lesions Aortic roots were isolated, frozen in an Optimal Cutting Temperature (O.C.T.) compound (Tissue Tek (Sakura)) on dry ice and stored at -80 C. Five-micrometer frozen tissue sections were cut starting at the aortic valve plane to cover 500mm in intervals of 50mm and stained with Oil Red O/Hematoxylin/Light green as previously described. Images were obtained using Nikon Eclipse 80i microscope with a 4x0.2 NA objective. The lesion area was measured using Fiji software; atherosclerosis lesion area was calculated as average of lesion areas at least 8 sections for each mouse.
Immune cells composition analysis by Flow Cytometry
Aortas were isolated from WT/Ldlr -/-, Il23 -/-/Ldlr -/-and Il22 -/-/Ldlr -/-mice, cut into small pieces followed by digesting in 2 ml of enzymatic cocktail, containing 450 U/ml collagenase type I, 250 U/ml collagenase type XI, 120 U/ml hyaluronidase type I, 120 U/ml DNAse I in 1x HBSS and incubated in a shaker at 37 C for 55 min. Obtained single cells suspension was stained with following antibodies: CD45-PerCP (30-F11), CD11b-eFluor 450 (M1/70), CD11c-Cy7PE (N418), TCRb-eFluor 780 (H57-597), CD4-PE (GK1.5) and LIVE/DEAD Yellow fixable dye (Invitrogen) and analyzed by flow cytometry (LSRII, BD Biosciences). For T-cell related cytokine production analysis, single-cell suspensions from aorta were stimulated in complete RPMI 1640 media with PMA+Ionomycin and Brefeldin A for 5h in vitro at 37 C in a CO 2 incubator. For intracellular myeloid cells osteopontin staining, cells were stimulated in complete DMEM media with LPS (100ng/ml) for 4h in the presence of Brefeldin A. After stimulation cells were fixed and permeabilized by Cytofix/Cytoperm kit (BD), and stained with IL-17A-Cy7PE (eBio17B7), IFNg-APC (XMG1.2) or OPN-APC (2F10) antibody.
Lamina propria lymphocyte (LPL) isolation was performed as described before (Grivennikov et al., 2012) . In brief, isolated intestines were removed and placed in ice-cold 5% fetal bovine serum (FBS) in HBSS and incubated twice in 20ml of 5mM EDTA in HBSS for 15 min at 37 C with rotation of 150 rpm. After incubation, IELs were removed by passing through a metal sieve into new tubes and the residual tissues (LPL) were chopped to make it almost homogeneous and digested in 5-6 ml collagenase type VIII (Sigma) (1mg/ml) in 5% FBS, HBSS for 35 min in shaking 37 C incubator. After incubation the solution was passed through 70mm cell strainer. Percoll gradient (40%/80%) separation of LPL was performed by centrifugation at 2200rpm for 25 min with slow acceleration and deceleration. LPL immune cells were collected from the interphase of Percoll gradient. Obtained cells suspension was stained with following antibodies: CD45-PerCP (30-F11), CD90.2-eFluor 450 (M1/70), TCRb-eFluor 700 (H57-597), CD4-APC (GK1.5) and LIVE/DEAD Yellow fixable dye (Invitrogen) and analyzed by flow cytometry (LSRII). For IL-22 cytokine production analysis, single-cell suspensions from the LPL and aorta were stimulated in complete RPMI 1640 media with IL-23 (50ng/mL), IL-2 (5ng/mL) and IL-6 (5ng/mL) recombinant cytokines for 14 hours at 37 C in a CO 2 incubator. Brefeldin A was added to retain the cytokines within the cell for last 4h of stimulation. After stimulation cells were fixed and permeabilized by Cytofix/Cytoperm kit (BD Biosciences), and stained with IL-22-PE (1H8PWSR). Flow cytometry data were analyzed using FlowJo software.
Immunofluorescent and Immunohistochemistry staining analysis
Frozen 5mm aortic root and colon sections were fixed for 10 min in acetone (Sigma-Aldrich) at RT and placed into 1% paraformaldehyde in 100mM sodium phosphate containing 60mM lysine and 7mM sodium periodate (Sigma-Aldrich), pH 7.4 on ice. The sections were incubated with avidin/biotin blocking kit (Vector laboratories) following incubation in a 5% normal goat serum and 1% BSA (Sigma) in PBS. Aortic root sections were stained overnight at 4 C with primary antibodies: hamster anti-CD11c (HL3), rat antiCD11b-FITC (M1/70), rat anti-CD3 (17A2) and rabbit smooth muscle actin, followed by staining with secondary antibodies for 1 h at RT: goat anti-FITC Alexa Fluor 488 (Molecular Probes), goat anti-hamster IgG DyLight 649 (Jackson Immunoresearch), goat anti-rat IgG Alexa Fluor 568 (Molecular Probes), and donkey anti-rabbit IgG Alexa Fluor 568.
Colon tissues without contents were fixed in Carnoy's fixative (60% ethanol, 30% chloroform, 10% glacial acetic acid) overnight, paraffin-embedded and stained for Mucin2 with rabbit anti-Muc2 (Santa Cruz), followed by goat anti-rabbit Alexa 488 (Life Technologies) secondary antibody staining.
RegIIIg and Mucin staining were performed on colon tissues fixed in 4% Paraformaldehyde overnight and 30% Sucrose at 4 C for 12h and frozen in O.C.T. compound (Tissue Tek (Sakura)) on dry ice.
Sections were counterstained with DAPI and embedded in Prolong Gold. Images were acquired on a Leica SP8 DM6000 inverted confocal microscope using HCX PLAPO 20x and 40x oil-immersion objectives at 405 nm, 488 nm, 563 nm and 633 nm excitation wavelength. Imaris Software was employed to adjust brightness and one-step smoothing on all images in parallel.
Immunohistochemistry staining for RegIIIg was performed on frozen 5mm colon sections that were fixing for 10 min in acetone (Sigma-Aldrich). Fixed sections were incubated in 3% H 2 O 2 solution in PBS at room temperature for 10 min to block endogenous peroxidase activity following by incubation with 5% normal goat serum in PBS for 1 hour at room temperature. Slides were stained overnight at 4 C with primary antibodies: rabbit anti-REGIIIg (Invitrogen) followed by staining with biotinylated secondary goat antibodies for 1h at RT. Streptavidin-HRP (BD, Pharmingen) was added for 30 min. Sections were developed with DAB substrate (0.05% DAB and 0.015% H 2 O 2 in PBS) for 3-5 min and counterstained with Hematoxylin (1-2min) and then immerged in bluing for 30 seconds. Tissue sections were dehydrated through 3 changes of alcohol (100%), 3 min each and cleared through 3 changes of xylene (Fisher Chemicals), 3 min each. Slides were mounted using Permount solution (Fisher).
For whole-mounts staining of large intestines, tissue fragments (1-2cm) were fixed in freshly prepared 4% paraformaldehyde (PFA) in PBS for 6-8h and incubated in 0.5% (wt/vol) saponin, 2% fetal bovine serum (FBS) (vol/vol), and 0.09% (wt/vol) azide in PBS for at least 18 h at 4 C. The same buffer was used for subsequent incubations with fluorescently labeled Phalloidin (Alexa Fluor 647) and YOYO-1 iodide (491/509) overnight at 4 C followed by 2h incubation at 37 C. Samples were washed with PBS and analyzed by microscopy.
TUNEL assay/Immunofluorescence staining Frozen 5mm aortic roots were fixing for 10 min in acetone (Sigma-Aldrich) at RT and placed into 1% paraformaldehyde in 100mM sodium phosphate containing 60mM lysine and 7mmM sodium periodate (Sigma-Aldrich) pH 7.4 on ice. Then slides were permeabilized with freshly prepared 0.1% Triton X-100, 0.1% sodium citrate solution and incubated with TUNEL reaction mixture for 60 minutes at 37 C in the dark. The sections were incubated with avidin/biotin blocking kit (Vector laboratories) followed by incubation in a 5% normal goat serum and 1% BSA (Sigma) in PBS. Aortic root sections were stained overnight at 4 C with primary antibodies: rat anti-CD11b-FITC (M1/70, BD Bioscience) followed by staining with secondary antibodies for 1 h at RT: goat anti-FITC Alexa Fluor 488 (Molecular Probes).
Gene expression analysis
The tissues (aorta, intestine or spleen) were homogenized with RNAse/DNase free 2.8mm Ceramic Beads using Omni Bead Ruptor 24 in PureZOL RNA Isolation Reagent (Bio-Rad Laboratories) followed by RNA isolation using Aurum Total RNA Fatty and Fibrous Tissue kit (Bio-Rad Laboratories) according to manufacturer's protocol. First strand cDNA was synthetized using the iScript Reverse Transcription Supermix (Bio-Rad Laboratories). Gene expression was analyzed by SYBR green real-time polymerase chain reaction (Bio-Rad Laboratories) using primers for RpL32, Spp1, Il1b, Tnf, Ifng, Il17a, Il22, Ccl2, Ccl5, Cxcl1, Reg3b, Reg3g, Muc2, Cd36, Itgam, Il12a, Il12b, Mrc1, Chi3l1, Chi3l3, Retnla, Abca1, Abcg1 . Gene expression was normalized to RpL32 expression. Data were analyzed using Prism statistical software (GraphPad). Omni Bead Ruptor 24 in ASL buffer (stool lysis buffer) (Qiagen) followed by DNA isolation using QIAamp DNA stool Mini Kit (Qiagen) according to manufacturer's protocol. QPCR was carried out using universal or bacterial strain-specific primers for 16S rRNA genes. The V4 region of the 16S rDNA gene was amplified by two round amplification PCR using Phusion High-Fidelity DNA-polymerase (NEB) with 100ng of input DNA. First round PCR (15 cycles): 515F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG 806R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC Second round PCR (10 cycles) with i5 and i7 Illumina barcode sequences: AATGATACGGCGACCACCGAGATCTACAC-i5-TCGTCGGCAGCGTC CAAGCAGAAGACGGCATACGAGAT-i7-GTCTCGTGGGCTCGG Amplicones were purified between and after the PCR reactions with Agencourt AMPure XP (Beckman Coulter, Inc.), libraries were quantified using KAPA Library Quantification Kit for Illumina Platforms (Kapa Biosystems) and size was estimated using Agilent Tapestation 4200 (Agilent). Libraries were pooled at equimolar concentration using Epmotion 5075 tmx automatic liquid handling machine (Eppendorf) and sequenced with 5% PhiX library added to the pool on Illumina MiSeq machine according to manufacture instructions using v3 kit (600 cycles). Fastq files were generated on Basespace (Illumina). On average 100,000 reads were obtained per sample, and after quality control filtering; on average 90,000 reads per sample were processed further. Chimeric sequences were filtered out of the FASTQ files containing the 16S rRNA gene sequences using the USEARCH (version 8.1.) utility's UCHIME implementation and the 'gold' database (version microbiomeutil-r20110519). The reads, thus filtered, were then binned into operational taxonomic units (OTUs) at 97% similarity using USEARCH's cluster_otus command. QIIME (1.9.1) scripts were used to classify and align the obtained OTUs (Namasivayam et al., 2017) . The assign_taxonomy.py script was used to assign taxonomy using the default RDP method (Wang et al., 2007) and GreenGenes database (DeSantis et al., 2006) . The statistical differences between the groups were estimated with non-parametric Mann-Whittney test and p-values were corrected for multiple tests using q-value 0.05 as a cutoff and data was visualized using heatmaps and PCA plots (Partek 6.6).
Microbiome analysis
Metagenomic whole genome shotgun (WGS) sequencing Metagenomic sequencing provides species-level resolution of bacteria, and depending on sequence depth, can quantify the nearcomplete genomic content of the collection of microbes in a particular sample, referred to as the sample's metagenome.
Whole genome shotgun (WGS) sequencing utilized the same extracted bacterial genomic DNA used for 16S rRNA gene compositional analysis and was done at Microbiome Core at NCI. Briefly, metagenomic DNA obtained from 16 samples was used to build paired-end shotgun sequencing libraries with the Illumina Nextera FLEX kit. Libraries were sequenced on the Illumina NextSeq 500 platform yielding 2 x 75 bp reads totaling between 2.9 and 4.9 Gbp of raw data. For each sample, raw reads were adapter trimmed and quality clipped using Trimmomatic v.0.36 (Bolger et al., 2014) . Trimmed reads were then aligned against the Mus musculus complete genome using bowtie v.2-2.3.4. Reads which did not align to the mouse genome were considered as pertaining to the microbiome and were used as input for read assembly using MEGAHIT v1.1.1 (Li et al., 2015) . The mean assembly rate for samples was 69% ± 13% of total reads being assembled into contigs of at least 500 bp. Contigs resulting from assembly were taxonomically classified by k-mer spectrum with kraken v.1.1 (Wood and Salzberg, 2014 ) using a custom built k-mer database comprising of all complete plus draft genomes present in NCBI's GenBank of bacteria, archaea, viruses, fungi, protozoa, plus the genomes of Homo sapiens and Mus musculus. Contigs identified as being Mus musculus were discarded. Contigs were annotated using prokka v.1.12 (Seemann, 2014) and the predicted metaproteome was functionally annotated using interproscan v.5.29-68.0 (Hunter et al., 2009) . The trimmed reads used as input for assembly were then aligned against the contigs using bowtie2 to gauge sequencing depth for each contig. Reads, which did not align to any contig (unassembled reads), were collected and themselves taxonomically classified by kraken using the aforementioned custom-built k-mer database. The relative abundance for each taxon was calculated as being the relative proportion of bases attributed to that taxon, coming from either unassembled reads or reads built into contigs, out of the total amount of bases sequenced for that sample. Relative abundances were expressed as parts per million.
The relative abundance of functions (taxonomy independent) was calculated in a similar manner, but considering only bases assembled into contigs, as each protein was predicted ab initio from the contigs. The number of bases sequenced for each protein-coding gene was measured from the contig sequencing depth. Because all the proteins were functionally characterized by Interproscan as to their functional domain signatures, the relative abundance of each functional protein signature within a sample was computed as being the relative proportion (expressed in parts per million) of the sum of the sequencing depths of all protein coding genes bearing that signature out of the sum of the sequencing depths of all the predicted proteins within the sample. It can thus be interpreted as the ''dose'' of a functional signature within the sample, independent of taxonomy.
Additional factor accounting for cage effect was added in the statistical model testing for unique and common effect of IL-22 and IL-23 deficiency in atherosclerotic mice.
Serum analysis of bacterial endotoxin (LPS)
Blood samples were drawn from WT, Il23 -/-or Il22 -/-transplanted Ldlr -/-mice and serums were collected via centrifugation for 10 min. Serum endotoxin level was determined using Pierce LAL Chromogenic Endotoxin Quantification Kit (Thermo Scientific) according to manufacture protocol. The results were analyzed using spectrophotometer.
TMAO analysis TMAO levels were quantified by stable isotope dilution liquid chromatography with on line electrospray ionization tandem mass spectrometry on a Shimadzu 8050 triple quadrupole mass spectrometer interfaced with UHPLC using d9(trimethyl)-TMAO as internal standard, as previously described (Wang et al., 2014b) .
Metabolomics
Mass spectrometry analysis was performed by the Proteomics and Metabolomics Facility at the Wistar Institute. Polar metabolites were extracted from serum using 80% methanol, and targeted quantitation of metabolites was performed on a SCIEX 5500 QTRAP triple quadrupole mass spectrometer equipped with a Turbo V source and coupled to a Shimadzu Nexera UHPLC system. Five microliters of each sample were injected onto a ZIC-pHILIC 2.1-mm i.d 3 150 mm column (EMD Millipore). Buffer A was 20 mM ammonium carbonate, 0.1% ammonium hydroxide; and buffer B was acetonitrile. The chromatographic gradient was run at a flow rate of 0.150 ml/min for 80-20% B over 20 min, 20-80% B over 0.5 min, and hold at 80% B for 7.5 min. Metabolites were targeted in positive and negative ion modes for a total of 163 selected reaction monitoring transitions. Electrospray ionization voltage was +5500 V in positive ion mode and À4500 V in negative ion mode. A minimum of 8 data points was acquired per detected metabolite. Peak areas from the total ion current for each metabolite-selected reaction monitoring transition were integrated using the MultiQuant v3.0.2 software (SCIEX).
Metabolome detection intensity levels were quantile normalized and log2-transformed. Significance of changes were tested using Limma package (Ritchie et al., 2015) version 3.36.1 combining mice genders and separately and results passing p<0.05 threshold were called significant. Additional factor accounting for cage effect was added in the statistical model testing for unique and common effect of IL-22 and IL-23 deficiency in atherosclerotic mice. Results related to TMAO pathway were reported as fold changes with significant effects highlighted.
LPS and TMAO supplementation
Beginning at 6 weeks of age, female and male Ldlr -/-were fed with a WD for 6 weeks and then injected i.p. with LPS (50mg per injection), TMAO (250 ml of 100mM solution per injection) or both metabolites together every 3 days for additional 3 weeks of WD feeding. After that, changes in atherosclerosis progression and inflammatory gene expression were analyzed. For the ex vivo experiments explanted aortas from C57BL/6 mice were stimulated in serum free DMEM media with LPS (100ng/ml), TMAO (200ng/ml) or both for 8h at 37 C in CO 2 incubator. For acute LPS and TMAO exposure studies, C57BL/6 female and male mice were injected with LPS (50mg) and TMAO (250 ml of 100mM solution per injection) and blood was collected after 4 hours following by immunomagnetic isolation of Ly6C positive monocytes using Easy Sep FITC Positive Selection Kit (StemCell Technologies) according to the manufacture protocol. Sorted cells were lysed in RLT buffer following with RNA isolation and Q-RT-PCR analysis. 
Scanning Electron Microscopy
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were analyzed using Prism software (GraphPad). Student's 2-tailed T-test and Wilcoxon signed-rank test was used to compare fold induction of gene expression by real-time PCR. ANOVA test was used for multiple comparisons. Microbiota composition was analyzed and visualized using Partek, Matlab and R packages. Standard statistical tests, such as t-test, ANOVA, PERMANOVA, PCA, t-SNE and others were performed and visualized using scatter plots and heatmaps. Picrust analysis was performed on biome file. Pathways outputs were analyzed using Partek and R. Data are expressed as mean ± SEM. *p<0.05, ** p <0.01, *** p <0.001. P value <0.05 was considered significant.
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw data files for 16SRNA and metagenomic microbiome sequencing analysis reported in this paper is NCBI Bioproject. Accession number PRJNA488231.
